Gene
RAF1
RAF1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (31), Actionable biomarkers (5), Trial mentions (203), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention RAF1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 5 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 12 of 8,738 | 0.14% | not measured | |
| 2025 | 6 of 8,875 | 0.07% | not measured | |
| 2024 | 15 of 8,597 | 0.17% | not measured | |
| 2023 | 20 of 8,275 | 0.24% | 17 of 11,460 | 0.15% |
| 2022 | 10 of 8,285 | 0.12% | 10 of 13,598 | 0.07% |
| 2021 | 13 of 8,692 | 0.15% | 37 of 15,045 | 0.25% |
| 2020 | 12 of 7,640 | 0.16% | 21 of 14,459 | 0.15% |
| 2019 | 7 of 7,300 | 0.10% | 23 of 12,159 | 0.19% |
| 2018 | 10 of 6,927 | 0.14% | 19 of 11,854 | 0.16% |
| 2017 | 14 of 6,558 | 0.21% | 30 of 11,595 | 0.26% |
Showing 10 of 37 years.
Assay-provider ledger (31)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Qiagen, Düsseldorf, Germany | Reagent supplier | Clinical validation | 1 | November 01, 2021 |
| SinoGeneClon Biotech Co., Ltd, Hangzhou, China | Reagent supplier | Clinical validation | 1 | November 01, 2021 |
| Thermo Fisher | Reagent supplier | Clinical validation | 1 | November 01, 2021 |
| Aushon BioSystems | Reagent supplier | Clinical validationAnalytical validation | 1 | June 21, 2021 |
| Tecan Group Ltd | Reagent supplier | Clinical validationAnalytical validation | 1 | June 21, 2021 |
Showing 5 of 31 assay-provider companies.
Actionable biomarkers (5)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation | Braf Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
| RAF1 overexpression | Sorafenib | response-associated | osteosarcoma | Cancer Genome Interpreter |
| RAF1 fusion | Sorafenib | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
| RAF1 fusion | Pan-raf Inhibitors | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
| RAF1 fusion | U0126 | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (203)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04906733 | Trial biospecimen (AACT) |
| NCT07103304 | Trial biospecimen (AACT) |
| NCT04292119 | Trial eligibility (AACT) |
| NCT06771544 | Trial eligibility (AACT) |
| NCT05970705 | Trial eligibility (AACT) |
Showing 5 of 203 trial mentions.
Target-disease associations (610)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| ALDH18A1-related de Barsy syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| ATTRV122I amyloidosis | cardiovascular disease | Mouse knockout (IMPC) |
| Abnormality of the cardiovascular system | phenotype | Variant curation (ClinVar / EVA) |
| Acanthamoeba keratitis | disorder of visual system | Mouse knockout (IMPC) |
Showing 5 of 610 associations.
Vendor sourcing (684)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Missens... | View ClinVar record SCV002012216.3 |
| A&D Instruments, Ltd | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | (non-exclusive; when CRP test is unavailable in medical records) associated with high or very high cardiovascular (CV) toxicity risk factors (according to th... | View trial NCT06778122 |
| A&D Instruments, Ltd | Trial collaborator | Mentioned in trial textTrial free-text mention | RAF | View trial NCT06778122 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The RAF1 c.1688G>A; p.Arg563Gln variant (rs727504827), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: ... | View ClinVar record SCV004562747.1 |
| Academic and Community Cancer Research United | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * 131I therapy =\< 6 months prior to registration; Note: 131I administered solely for diagnostic purposes is not considered 131I therapy * External beam r... | View trial NCT02393690 |
Showing 5 of 684 sourcing records.
Trial-cited literature (368)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome. | Frontiers in pediatrics | 2025 | 3 |
| Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). | Trials | 2025 | 1 |
| Multidrug-Resistant Sepsis: A Critical Healthcare Challenge. | Antibiotics (Basel, Switzerland) | 2024 | 100 |
| LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. | BMC cancer | 2024 | 57 |
| Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial. | BMC cancer | 2024 | 9 |
Showing 5 of 368 papers.
Protein variant mentions (108)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A2322T | 1 | 2020 | PMID 32326472 |
| p.A237T | 1 | 2015 | PMID 25741868 |
| p.A2827T | 1 | 2020 | PMID 32326472 |
| p.A42T | 2 | 2015 to 2021 | PMID 33500567, PMID 25741868 |
| p.A42V | 1 | 2015 | PMID 25741868 |
Showing 5 of 108 variants.
Literature-extracted relations (40)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| DOXORUBICIN | Chemical | negative_correlate |
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. | 2020 |
| Sorafenib | Chemical | negative_correlate |
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. | 2020 |
| Ivermectin | Chemical | negative_correlate |
The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. | 2020 |
| Sorafenib | Chemical | negative_correlate |
Molecular insight of regorafenib treatment for colorectal cancer. | 2019 |
| Emetine Hydrochloride | Chemical | negative_correlate |
Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. | 2018 |
Showing 5 of 40 relation assertions.
Organizations publishing (321)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 35 | 2002 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 19 | 2010 to 2023 |
| Harvard Medical School | Academic | 14 | 1997 to 2023 |
| Dana-Farber Cancer Institute | Other | 13 | 2013 to 2023 |
| Mass General Brigham | Hospital | 12 | 1988 to 2023 |
Showing 5 of 321 organizations.
Where RAF1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
504 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.